Aspects of management of patients with cholelithiasis: clinical example

Gallstone disease (GSD) is currently one of the most common diseases of the gastrointestinal tract, especially among people of working age, and has a clear tendency to increase and expand the age range towards rejuvenation. To date, the possible links in the pathogenesis of cholelithiasis have been well studied and described, risk factors and clinical manifestations have been studied and described, among which the asymptomatic course of cholelithiasis, which is often noted at the first latent stage of the disease, is important. It is at this stage that preventive conservative treatment allows most patients to avoid stone formation. However, after ascertaining biliary sludge, therapeutic correction is not carried out. Among the drugs used as oral litholytic therapy, ursodeoxycholic acid (UDCA) is used, which is effective for predominantly cholesterol (X-ray negative) calculi up to 15–18 mm in size or biliary sludge in the form of putty bile. It is known that UDCA changes the ratio of cholesterol/bile acids in bile, which contributes to the mobilization of cholesterol from gallstones and cause their partial or complete dissolution, and prevent the formation of new calculi. At the same time, the use of oral litholytic therapy is also possible at stage 2 of cholelithiasis with asymptomatic or rare attacks of biliary colic, the absence  of violations of the patency of the extrahepatic bile ducts, and also if        the patient does not agree to cholecystectomy in order to stabilize the process of stone formation. This article presents a review of the literature on the etiopathogenetic, clinical features of cholelithiasis, as well as the treatment of cholelithiasis, primarily with an emphasis on the prevention of this disease. An analysis of a clinical case is given with a discussion of rational pharmacocorrection in cholelithiasis.

1. Ilchenko A.A. Biliary sludge: causes of formation, diagnosis, treatment. Consilium Medicum. Gastroenterology (Suppl.). 2012;(2):18–21. (In Russ.) Available at: https://omnidoctor.ru/upload/iblock/fe8/fe806ea5e5f8edc0d-b173acd20238530.pdf.

2. Ivashkin V.T., Mayev I.V., Baranskaya Y.K., Okhlobystin A.V., Shulpekova Yu.O., Trukhmanov A.S. et al. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):64–80. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/61/48.

3. Marschall H.U., Einarsson C. Gallstone disease. J Intern Med. 2007;261(6):529–542. https://doi.org/10.1111/j.1365-2796.2007.01783.x.

4. Nakeeb A., Comuzzie A.G., Martin L., Sonnenberg G.E., Swartz-Basile D., Kissebah A.H., Pitt H.A. Gallstones: genetics versus environment. Ann Surg. 2002;235(6):842–849. https://doi.org/10.1097/00000658-200206000-00012.

5. Saveliev V.S., Petukhov V.A. Cholelithiasis and maldigestion syndrome. Moscow: Borges; 2011. 258 p. (In Russ.) Available at: https://www.gastroscan.ru/literature/pdf/Saveliev-Petukhov-2010.pdf.

6. Carotti S., Guarino M.P., Cicala M., Perrone G., Alloni R., Segreto F. et al. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motil. 2010;22(8):866–873. https://doi.org/10.1111/j.1365-2982.2010.01510.x.

7. Maev I.V., Gulenchenko Yu.S., Dicheva D.T., Andreev D.N., Gurtovenko I.Yu. Clinical significance of biliary sludge as a pre-stone stage of cholelithiasis. Consilium Medicum. 2013;15(8):44–47. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/93877.

8. Guarino M.P., Cong P., Cicala M., Alloni R., Carotti S., Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut. 2007;56(6):815–820. https://doi.org/10.1136/gut.2006.109934.

9. Bordin D.S. Recommendations of the gastroenterologists scientific society of Russia in the diagnosis and treatment of gallstone disease. Experimental and Clinical Gastroenterology. 2012;(4):114–123. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=21611699.

10. Buser K.B. Endoscopically obtained bile aspirate is an accurate adjunct in the diagnosis of symptomatic gallbladder disease. JSLS. 2010;14(4):490–493. https://doi.org/10.4293/108680810X12924466007764.

11. Ilchenko A.A. Modern view on the problem of biliary sludge. RMJ. 2010;18(28):1707–1713. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Sovremennyy_vzglyad_na_problemu_biliarnogo_sladgha/.

12. Abgadzhava E.Z., Telnykh Yu.V. Pathogenetic therapy and of the gallbladder sludge outcomes. Experimental and Clinical Gastroenterology. 2016;(4):67–71. (In Russ.) Available at: https://www.nogr.org/jour/article/view/180.

13. Kazyulin A.N., Shestakov V.A., Goncharenko A.Yu., Kalyagin I.E., Pavleeva E.E. Practice and prospects of clinical application of ursodeoxycholic acid preparations. RMJ. Medical Review. 2018;(3):45–52. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Praktika_i_perspektivyklinicheskogo_primeneniya_preparatovursodezoksiholevoy_kisloty.

14. Ilchenko A.A. Is it possible to effectively prevent cholecystolithiasis? RMJ. 2010;18(18):1116–1122. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Vozmoghna_li_effektivnaya_profilaktika_holecistolitiaza.

15. Portincasa P., Di Ciaula A., Wang H.H., Moschetta A., Wang D.Q. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem. 2009;16(12):1531–1542. https://doi.org/10.2174/092986709787909631.

16. Trowbridge R.L., Rutkowski N.K., Shojania K.G. Does this patient have acute cholecystitis? JAMA. 2003;289(1):80–86. https://doi.org/10.1001/jama.289.1.80.

17. Grishchenko E.B. Gallstone disease treatment: challenges and perspectives. Consilium Medicum. 2018;20(8):42–52. (In Russ.) Available at: https://omnidoctor.ru/upload/iblock/423/42360620dac28305dfc6e5ded226e9f1.pdf.

18. Viktorova I.A., Trukhan D.I. Experience with the use of Urdox in the treatment of biliary sludge. International Journal of Applied and Basic Research. 2011;(11):24. (In Russ.) Available at: https://applied-research.ru/ru/article/view?id=1833.

19. Minushkin O.N., Elizavetina G.A., Ivanova O.I., Shaposhnikova O.F. Ursodeoxycholic acid in the treatment of patients with biliary sludge. Effective Pharmacotherapy. Gastroenterology. 2012;(3):10–12. (In Russ.) Available at: https://umedp.ru/upload/iblock/8f8/8f8aaa2764dc1516fad8573172b31b5d.pdf.

20. Simanenkov V.I., Sablin O.A., Lutaenko E.A., Ilchishina T.A. Possibilities of using ursodeoxycholic acid (Urdox drug) for biliary dyskinesia. Gastroenterology of St Petersburg. 2010;(2–3):23–26. (In Russ.) Available at: http://gastroforum.ru/wp-content/uploads/2012/06/GSP_2-3_2010_23-26_Simanenkov.pdf.

21. Simanenkov V.I., Lutaenko E.A. Guidelines for the use of ursodeoxycholic acid (Urdox) in patients with biliary dyskinesia. (In Russ.) Available at: https://pandia.ru/text/78/102/646.php.

22. Mekhtiev S.N., Mekhtieva O.A. Fatty liver disease as a risk factor for cardiovascular events in patients with arterial hypertension. Lechaschi Vrach. 2015;(5):1–6. (In Russ.) Available at: https://www.lvrach.ru/2015/05/15436229.